风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

天然型调节性T细胞（nTreg）发育分化的研究进展

2014-01-03 陈辉 赵勇 生物化学与生物物理学进展

nTregFOXP3CD25胸腺免疫耐受
关注

   CD4 CD25 调节性T细胞(Treg)对维持自身免 疫耐受及调控免疫应答水平发挥非常重要的作用．Treg的缺失或紊乱导致如多发性硬化症、1型糖尿病等自身免疫性疾病的发生．研究发现，Treg在肿瘤免 疫、感染免疫和移植免疫耐受中也发挥关键作用．根据来源不同，可将Treg分为胸腺来源的天然型Treg(natural Treg)和外周诱导型Treg(induced

   CD4 CD25 调节性T细胞(Treg)对维持自身免 疫耐受及调控免疫应答水平发挥非常重要的作用．Treg的缺失或紊乱导致如多发性硬化症、1型糖尿病等自身免疫性疾病的发生．研究发现，Treg在肿瘤免 疫、感染免疫和移植免疫耐受中也发挥关键作用．根据来源不同，可将Treg分为胸腺来源的天然型Treg(natural Treg)和外周诱导型Treg(induced Treg)两群．天然型Treg(nTreg)是由胸腺发育分化成熟的，nTreg存在于胸腺CD4单阳性细胞中，表达CD4、CD25及叉头转录因子 Foxp3，主要通过细胞与细胞之间直接接触发挥免疫抑制功能．研究表明，nTreg在胸腺中发育分化受到十分复杂的细胞、分子网络调控．胸腺微环境、T 细胞受体、共刺激分子、IL-2等信号都可影响nTreg的发育分化．本文将主要对胸腺nTreg的发育分化过程及分子调控等方面进行综述．天然型调节性T细胞发育分化的研究进展.pdf

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1347009, encodeId=6581134e0096e, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380400, encodeId=46b21380400df, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477183, encodeId=936014e71833c, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-05 neurowu

    #发育#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1347009, encodeId=6581134e0096e, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380400, encodeId=46b21380400df, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477183, encodeId=936014e71833c, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-05 mashirong

    #研究进展#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1347009, encodeId=6581134e0096e, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380400, encodeId=46b21380400df, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477183, encodeId=936014e71833c, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-05 12498484m48(暂无昵称)

    #Treg#

    0